INTRODUCTION: Abnormalities of serum sodium are common after subarachnoid hemorrhage (SAH) and have been linked to poor outcome. This study analyzed whether abnormal serum sodium levels are associated with cardiac outcomes and mortality after subarachnoid hemorrhage (SAH). METHODS: In a prospective cohort study of SAH patients, the primary predictor variable was subjects' sodium level. Hypernatremia was defined as sodium >143 mmol/L and hyponatremia was <133 mmol/L. Cardiac troponin I (cTi) was measured and echocardiography was performed on three study days. Dichotomous outcome variables were cTi > 1.0 microg/L, left-ventricular ejection fraction (LVEF) <50%, presence (vs absence) of regional wall motion abnormalities (RWMA) of the LV, pulmonary edema, and death. Additional analyses studied the degree of hypernatremia and sodium supplementation, and the temporal relationship between hypernatremia and cardiac outcomes. RESULTS: The study included 214 subjects. Forty-eight subjects (22%) were hypernatremic on at least one study day, and 45 (21%) were hyponatremic. After multivariate adjustment, hypernatremia was an independent predictor of LVEF <50% (OR 4.7, CI 1.3-16.2, p = 0.015), elevated cTi (OR 3.7, CI 1.2-11.9, p = 0.028), and pulmonary edema (OR 4.1 CI 1.4-1.5, p = 0.008). It was not, however a statistically significant predictor of mortality (p = 0.075). CONCLUSION: In the acute period after SAH, hypernatremia is associated with adverse cardiac outcomes and death. SAH patients with hypernatremia should be monitored for evidence of cardiac dysfunction.
INTRODUCTION: Abnormalities of serum sodium are common after subarachnoid hemorrhage (SAH) and have been linked to poor outcome. This study analyzed whether abnormal serum sodium levels are associated with cardiac outcomes and mortality after subarachnoid hemorrhage (SAH). METHODS: In a prospective cohort study of SAHpatients, the primary predictor variable was subjects' sodium level. Hypernatremia was defined as sodium >143 mmol/L and hyponatremia was <133 mmol/L. Cardiac troponin I (cTi) was measured and echocardiography was performed on three study days. Dichotomous outcome variables were cTi > 1.0 microg/L, left-ventricular ejection fraction (LVEF) <50%, presence (vs absence) of regional wall motion abnormalities (RWMA) of the LV, pulmonary edema, and death. Additional analyses studied the degree of hypernatremia and sodium supplementation, and the temporal relationship between hypernatremia and cardiac outcomes. RESULTS: The study included 214 subjects. Forty-eight subjects (22%) were hypernatremic on at least one study day, and 45 (21%) were hyponatremic. After multivariate adjustment, hypernatremia was an independent predictor of LVEF <50% (OR 4.7, CI 1.3-16.2, p = 0.015), elevated cTi (OR 3.7, CI 1.2-11.9, p = 0.028), and pulmonary edema (OR 4.1 CI 1.4-1.5, p = 0.008). It was not, however a statistically significant predictor of mortality (p = 0.075). CONCLUSION: In the acute period after SAH, hypernatremia is associated with adverse cardiac outcomes and death. SAHpatients with hypernatremia should be monitored for evidence of cardiac dysfunction.
Authors: N Parekh; B Venkatesh; D Cross; A Leditschke; J Atherton; W Miles; A Winning; A Clague; C Rickard Journal: J Am Coll Cardiol Date: 2000-10 Impact factor: 24.094
Authors: N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger Journal: J Am Soc Echocardiogr Date: 1989 Sep-Oct Impact factor: 5.251
Authors: Adnan I Qureshi; M Fareed K Suri; Gene Y Sung; Robert N Straw; Abutaher M Yahia; Mustafa Saad; Lee R Guterman; L Nelson Hopkins Journal: Neurosurgery Date: 2002-04 Impact factor: 4.654
Authors: Ellen Deibert; Benico Barzilai; Alan C Braverman; Dorothy Farrar Edwards; Venkatesh Aiyagari; Ralph Dacey; Michael Diringer Journal: J Neurosurg Date: 2003-04 Impact factor: 5.115
Authors: Jan Claassen; An Vu; Kurt T Kreiter; Robert G Kowalski; Evelyn Y Du; Noeleen Ostapkovich; Brian-Fred M Fitzsimmons; E Sander Connolly; Stephan A Mayer Journal: Crit Care Med Date: 2004-03 Impact factor: 7.598
Authors: G Parenti; P C Cecchi; B Ragghianti; A Schwarz; F Ammannati; P Mennonna; A Di Rita; P Gallina; N Di Lorenzo; P Innocenti; G Forti; A Peri Journal: J Endocrinol Invest Date: 2010-08-31 Impact factor: 4.256
Authors: Melissa M J Chua; Alejandro Enríquez-Marulanda; Santiago Gomez-Paz; Yosuke Akamatsu; Mohamed M Salem; Georgios A Maragkos; Luis C Ascanio; Khalid A Hanafy; Corey R Fehnel; Christopher S Ogilvy; Justin Moore; Ajith J Thomas Journal: J Stroke Cerebrovasc Dis Date: 2021-11-05 Impact factor: 2.136
Authors: Justine H Ryu; Brian P Walcott; Kristopher T Kahle; Sameer A Sheth; Randall T Peterson; Brian V Nahed; Jean-Valery C E Coumans; J Marc Simard Journal: Neurocrit Care Date: 2013-10 Impact factor: 3.210
Authors: Thomas Namdar; Peter Leonard Stollwerck; Felix Hagen Stang; Georgios Kolios; Thomas Lange; Peter Mailänder; Frank Siemers Journal: Ger Med Sci Date: 2011-06-08